it's the opposite of a pump and dump! Inmed has built its value over YEARS of steady, keep-the-course management.
From the beginning, they've steadily put together a world class team of respected industry professionals, working toward a clear set of objectives that are based on extremely solid concepts. When you compare what Inmed is doing to GW Pharma, it's actually shocking to realize that Inmed has far more arrows in its quiver and many more potential revenue streams than it's 'big sister'; database & patentable biosynthesis tech, smaller physical footprint requirements/ecological advantages, compound quality/consistency advantages, compounds in development, etc.
What does GW have? Product closer to market, that's it. But with legalization sweeping across North America, and the opioid crisis in full blaze, the FDA will be pressured to fast track alternative, less addictive treatments. I predict that, in a few years, GW will be only one among many pharmas with product in the market. But Inmed has the potential to be in a class above them all.
When I think of a pump and dump, I think slick presentations and a monotonous drumbeat of 'positives' that amount to not much overall. In Inmed's case, there's been very little done in branding and positioning. Retaining a PR agency is the only move they've made, but the news has been steady and restrained. Public awareness is still statistically 0% :)
I'll hold for a 100 bagger :)
